Daily Media Digest July 28, 2020

Interferon and COVID-19: ‘We should be stockpiling’
Regina Leader-Post
“Fish, a professor of immunology at the University of Toronto and a researcher at the University Health Network, has been waiting, rather impatiently, …”
TAGS: COVID-19, interferon, innovative treatment

What constitutes a second wave in Canada?
CTV News
“Steven Hoffman, a professor of global health, law, and political science at York University in Toronto and director of the Global Strategy Lab, said a “wave” is an imprecise term that is used colloquially to highlight the overall shape of an epidemic curve in terms of the number of new cases per day.”
TAGS: COVID-19, public health, infection control

World-first clinical trial aims to protect cancer patients from COVID-19
The Ottawa Hospital
“Patients receiving cancer treatments are the most at risk because the treatments further weaken their immune system. This at-risk population is quite large – over 90,000 people received radiotherapy or chemotherapy treatments in Ontario alone in 2019.”
TAGS:  COVID-19, cancer, vulnerable population

Free COVID-19 mental health service enters new phase in response to public need
UBC Faculty of Medicine
“Thanks to private donor funding, university support and partnerships with BCPA, Vancouver Coastal Health and Kelty’s Key, a virtual walk-in …”
TAGS: COVID-19, mental health, pandemic

SFU-led global COVID-19 gender study to expand with $2M grant
Simon Fraser University News
“SFU Faculty of Health Sciences research associate Julia Smith. research. SFU-led global COVID-19 gender study to expand with $2M grant.”
TAGS: COVID-19, gender study, innovative research

Breakthrough in autism spectrum research finds genetic ‘wrinkles’ in DNA could be a cause
CTV News
“Current research estimates that genetic factors should be found in anywhere from 50 to 90 per cent of individuals with ASD. Scientists already know of …”
TAGS: autism spectrum disorder, genetic links, children and youth health

We can eliminate Hepatitis C in Canada by 2030
Canada NewsWire
“AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, firmly supports efforts to eliminate hepatitis C. In Canada, an estimated 250,000 people are living with hepatitis C but almost half (44%) of Canadians infected are unaware they are living with the disease.1…”
TAGS: Hepatitis C, innovative treatment